Private Advisor Group LLC bought a new stake in ADMA Biologics Inc (NASDAQ:ADMA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 52,091 shares of the biotechnology company’s stock, valued at approximately $235,000.

A number of other institutional investors have also recently bought and sold shares of the business. Millennium Management LLC boosted its position in shares of ADMA Biologics by 254.0% in the fourth quarter. Millennium Management LLC now owns 67,533 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 48,455 shares during the period. BlackRock Inc. boosted its position in shares of ADMA Biologics by 59.5% in the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 15,115 shares during the period. Spark Investment Management LLC bought a new position in shares of ADMA Biologics in the first quarter worth approximately $102,000. JPMorgan Chase & Co. bought a new position in shares of ADMA Biologics in the first quarter worth approximately $182,000. Finally, Element Capital Management LLC bought a new position in shares of ADMA Biologics in the first quarter worth approximately $118,000. 56.38% of the stock is currently owned by institutional investors.

ADMA stock opened at $6.26 on Thursday. ADMA Biologics Inc has a one year low of $2.01 and a one year high of $6.96. The company has a debt-to-equity ratio of 0.79, a quick ratio of 8.88 and a current ratio of 10.65.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Friday, August 10th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The company had revenue of $4.66 million during the quarter, compared to analysts’ expectations of $5.35 million. equities research analysts anticipate that ADMA Biologics Inc will post -1.31 earnings per share for the current fiscal year.

A number of research firms have weighed in on ADMA. Maxim Group reiterated a “buy” rating and issued a $12.00 price target on shares of ADMA Biologics in a research report on Wednesday, September 5th. BidaskClub upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. ValuEngine upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, July 26th. Chardan Capital began coverage on shares of ADMA Biologics in a research report on Monday, July 30th. They issued a “buy” rating and a $10.00 price target for the company. Finally, Oppenheimer began coverage on shares of ADMA Biologics in a research report on Thursday, July 12th. They issued a “buy” rating and a $13.00 price target for the company. Seven analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $9.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.